We got to know BioNTech, one of the largest companies operating in the field of medicine, with the Covid-19 pandemic. At the end of the 11-month period, the German company that developed the first approved vaccine received promising news about the cancer vaccine. Ozlem Türeci, co-founder of BioNTech, spoke about his future work and cancer vaccine in an interview.
The couple, who have been working on the mRNA-based cancer vaccine for some time, issued a hopeful statement.
BioNTech co-founder Özlem Türeci spoke about the cancer vaccine
With the Coronavirus outbreak still on the agenda that the world still hasn’t recovered from, there’s a more general threat, a promising statement about cancer. In an interview with the New York Post, türeci said the mRNA system, which is also used in the Covid-19 vaccine, will be used in the cancer vaccine. This method of developing a vaccine, which triggers the immune system for the production of proteins to fight against the virus, basically allows to bring information to the body. The use of this method in the Covid-19 vaccine released by the company shows us an example.
Cancer vaccines based on the mRNA system still have several years to go before they can be used, the interview said. It was also emphasized that it is very difficult to make predictions about the emergence of such vaccines. After the outbreak of the Covid-19 pandemic, the priority of the studies related to the cancer vaccine has a part to play in the release date.
Türeci, who received the order of merit representing honor in Germany with his wife Ugur Sahin at yesterday’s ceremony, also spoke about this situation. In a statement, they said it was a great honour but we could not have done it alone. There’s a lot of work involved. Our team, partners, governments and regulators at BioNTech; We’ve all worked together.